8-KRegulation FD

GILEAD SCIENCES, INC. 8-K Report, Regulation FD Disclosure (Aug 9, 2013)

Filed August 9, 2013For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) has reached a settlement agreement with Lupin Limited regarding patent litigation concerning Gilead's sustained release ranolazine product, Ranexa®. The litigation, initiated by Gilead in July 2010 following Lupin's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ranexa, centered on the validity and infringement of ten patents covering the drug. Lupin had alleged these patents were invalid, unenforceable, or would not be infringed by their generic product. The settlement, agreed upon on August 9, 2013, allows Lupin to launch a generic version of Ranexa on February 27, 2019, subject to certain conditions and regulatory review by the Federal Trade Commission and Department of Justice. This resolution brings an end to a multi-year legal dispute, providing clarity on the market exclusivity for Ranexa and a defined timeline for generic entry.

Key Highlights

  • 1Gilead Sciences settled patent litigation with Lupin Limited regarding Ranexa® (ranolazine).
  • 2The settlement allows Lupin to market a generic version of Ranexa.
  • 3Generic Ranexa launch is permitted starting February 27, 2019.
  • 4The litigation involved allegations by Lupin challenging the validity and enforceability of ten Gilead patents for Ranexa.
  • 5Gilead had previously sued Lupin for patent infringement in July 2010.
  • 6The settlement agreement is subject to approval by the Federal Trade Commission and Department of Justice.

Frequently Asked Questions

The main outcome is that Gilead Sciences and Lupin Limited have resolved their patent litigation concerning Ranexa. The settlement permits Lupin to launch a generic version of Ranexa, but not before February 27, 2019.

The dispute was about patent infringement. Lupin filed an ANDA for a generic ranolazine and alleged that ten of Gilead's patents for Ranexa were invalid, unenforceable, or would not be infringed. Gilead contended that Lupin infringed its valid and enforceable patents.

Under the settlement agreement, Lupin is allowed to launch its generic version of Ranexa on February 27, 2019, provided certain conditions are met and regulatory approvals are obtained.

While this 8-K filing focuses on the settlement and the future launch date of the generic, it does not provide specific details on the immediate financial impact on current Ranexa revenue. However, the agreement defines a clear timeline for generic competition, which investors can use in their financial modeling for future periods.